Trial Profile
Phase I/II Dose-Escalation Trial of Combination Fractionated-dose 177Lu-J591 and 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Gallium (68Ga) gozetotide
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Jul 2020 Status changed from recruiting to discontinued.
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium.
- 30 Jul 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.